Brief: Ceapro Gains Approval From Health Canada For Protocol Expansion Of Current Clinical Study Assessing Beta Glucan As A Cholesterol-Lowering Agent
05/02/2020 13:20
Feb 5 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC. ANNOUNCES APPROVAL FROM HEALTH CANADA FOR
PROTOCOL
EXPANSION OF CURRENT CLINICAL STUDY ASSESSING BETA GLUCAN AS A
CHOLESTEROL-LOWERING AGENT
Source text for Eikon: ID:nGNX8d6KcL
Further company coverage: CZO.V
(Reuters.Briefs@thomsonreuters.com)
Recent news on Ceapro
See all newsBrief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases